Volpara Receives Regulatory Clearance in Japan

Wellington, NZ, 13 November 2017: Volpara Health Technologies ("Volpara"; ASX: VHT), a digital health company focused on the early detection of breast cancer by improving quality of screening, is pleased to announce the full **Volpara®Enterprise™** suite of products has now received regulatory approval as a Class II medical device in Japan.

Japan has some 65 million women, screening around 5 million of them each year for breast cancer using mammography, and is thus a potential major market for Volpara. It is estimated that Japan has around 3,200 mammography machines, making it one of the world's largest users of mammography outside the US.

The incidence of breast cancer is rapidly increasing in Japan, with breast cancer now one of the leading causes of cancer death, accounting for 20.4% of all new cancers. For this reason, breast cancer screening and increasing the compliance surrounding screening are areas of focus for the government. Women aged 40–69 are encouraged to undergo a breast screen every two years, and breast density notification is under discussion.

Volpara will launch the products in Japan via Breast Healthcare, its Japanese distributor (sales and installation), supported by the Volpara APAC sales team. The company already has multiple research sites installed and active with **Volpara®Density™** software, including Hokkaido Cancer Centre, Niigata Cancer Centre, Hokuto Hospital and Showa University School of Medicine; and formally launched **Volpara®Enterprise™** software at the Japanese Association of Breast Cancer Screening meeting held in Tokushima last week.

"We regard Japan as an extremely important market due to its size and density notification discussions, and our track record with leading research institutes," said Dr Ralph Highnam, Chief Executive Officer of Volpara.

"We also know it has a higher proportion of women with dense breasts compared to the West. A study conducted at Showa University School of Medicine with **Volpara®Density™** software showed approximately 80% of their population had dense breasts, compared to a more typical 40–50% in the West. The study also showed that cancer detection using mammography is very good in fattier breasts, but up to 30% of cancers in extremely dense breasts are being missed. Japan has a growing issue with breast cancer which we believe we can help with."

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density and quality.

VHT has numerous patents, trademarks and regulatory clearances, including FDA and CE, supporting its technology and services. An ASX-listed company that raised A$20M through an IPO and subsequent share placement and rights issue in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722